What is the 13F Pro Quality Score for SGRY?

13F Pro ranks Surgery Partners, Inc. (SGRY) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SGRY's current score at https://13fpro.ai/research/SGRY (free sign-up required for the full ranking).

Where does 13F Pro source SGRY data?

All Surgery Partners, Inc. fundamentals and ownership data come directly from SEC EDGAR. Surgery Partners, Inc. files with the SEC under CIK 1638833. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SGRY in?

Surgery Partners, Inc. (SGRY) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SGRY research updated on 13F Pro?

SGRY's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Surgery Partners, Inc.(SGRY)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1638833 SGRY stock profile & AI dashboard →

13F Pro Quality Score

48.0/100

Rank #1,578 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

62.7/100

Profitability

29.5/100

Balance Sheet

31.2/100

Earnings Quality

30.0/100

Free Cash Flow

44.7/100

Institutional Flow

42.2/100

Revenue Scale

71.3/100

Dilution Risk

76.9/100

SGRY Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Surgery Partners, Inc. (SGRY), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SGRY at 48.0/100 on a 32-signal composite quality model, placing it at rank #1,578 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (29.5) and earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Surgery Partners, Inc. reports quarterly revenue of $810.9M, net income of $-35.9M, an operating margin of 8.1%. Top institutional holders of SGRY by reported 13-F value include BAIN CAPITAL INVESTORS, JANUS HENDERSON GROUP PLC, Pentwater Capital Management, based on the most recent SEC filings. SGRY trades on the Nasdaq exchange and files with the SEC under CIK 1638833. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGRY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Surgery Partners, Inc. directly from SEC EDGAR. Surgery Partners, Inc.'s 13F Pro composite quality score has ranged between 8 and 59 since 2026, currently 48.0 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

✦

Fun facts about Surgery Partners, Inc.

Quirks, history, and lore behind SGRY — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare services company · listed on Nasdaq · headquartered in Tennessee · operates in the outpatient segment of the medical industry.
2
The Numbers
Generates roughly $2–3 billion in annual revenue and operates or manages hundreds of surgical facilities across more than 30 states — a footprint that keeps expanding.
3
The History
Built largely through acquisitions, the company has grown by snapping up independent surgical facilities and folding them into a national network since its early days in the 2010s.
4
The Secret
Its business model bets on the decade-long shift of complex procedures out of expensive hospitals and into lower-cost, physician-friendly ambulatory settings — a trend regulators and insurers actively encourage.
5
The Lore
Private equity giant H.I.G. Capital helped assemble the company before its public debut, and major investor Bain Capital has held a significant stake — giving this mid-cap a very blue-chip back story.
6
The Giveaway
Its name literally tells you what it does and where it does it: surgical procedures, handled by a network of ambulatory surgery centers, run by a company whose ticker is SGRY.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$810.9M

Net Income

Q1 2026

$-35.9M

Free Cash Flow

Q1 2026

$-4.3M

Operating Margin

Q1 2026

8.1%

ROIC

Q1 2026

1.2%

D/E Ratio

Q1 2026

2.20

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.5% YoY

$3.11BFY 2024

FY21 $2.23BFY22 $2.54BFY23 $2.74BFY24 $3.11B

Net Income

-1312.6% YoY

$-168.1MFY 2024

FY21 $-70.9MFY22 $-54.6MFY23 $-11.9MFY24 $-168.1M

Operating Income

+6.3% YoY

$348.8MFY 2024

FY21 $302.2MFY22 $345.2MFY23 $328.0MFY24 $348.8M

EPS (Diluted)

-1377.8% YoY

$-1.33FY 2024

FY21 $-1.12FY22 $-0.59FY23 $-0.09FY24 $-1.33

Total Assets

+14.7% YoY

$7.89BFY 2024

FY21 $6.12BFY22 $6.68BFY23 $6.88BFY24 $7.89B

Total Debt

+21.9% YoY

$3.51BFY 2024

FY21 $3.02BFY22 $2.70BFY23 $2.88BFY24 $3.51B

Op. Cash Flow

+2.1% YoY

$300.1MFY 2024

FY21 $87.1MFY22 $158.8MFY23 $293.8MFY24 $300.1M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$3.11B +13.5%	$2.74B +8.0%	$2.54B +14.1%	$2.23B +19.6%	$1.86B +1.6%	$1.83B
Net Income	$-168.1M -1312.6%	$-11.9M +78.2%	$-54.6M +23.0%	$-70.9M +38.9%	$-116.1M -55.2%	$-74.8M
Operating Income	$348.8M +6.3%	$328.0M -5.0%	$345.2M +14.2%	$302.2M +65.1%	$183.0M -22.4%	$235.9M
EPS (Diluted)	$-1.33 -1377.8%	$-0.09 +84.7%	$-0.59 +47.3%	$-1.12 +64.9%	$-3.19 -39.3%	$-2.29
Total Assets	$7.89B +14.7%	$6.88B +2.9%	$6.68B +9.2%	$6.12B +13.0%	$5.41B +7.9%	$5.02B
Total Debt	$3.51B +21.9%	$2.88B +6.7%	$2.70B -10.7%	$3.02B +2.6%	$2.94B +10.9%	$2.65B
Operating Cash Flow	$300.1M +2.1%	$293.8M +85.0%	$158.8M +82.3%	$87.1M -64.7%	$246.9M +90.7%	$129.5M

AI Insight: SGRY Financial Trends

Surgery Partners shows volatile quarterly performance with persistent losses despite $3.6B revenue run-rate and rising debt burden.

• Revenue grew from $762M in Q2 2024 to $811M in Q1 2026, showing overall upward trajectory despite quarterly volatility.

• Total debt increased from $3,132M in Q2 2024 to $3,714M in Q1 2026, rising $582M over eight quarters.

• Operating cash flow remains highly volatile, dropping to just $6M in Q1 2025 and $12M in Q1 2026.

• Equity declined steadily from $1,952M in Q2 2024 to $1,688M in Q1 2026, eroding shareholder value.

⚠ Operating cash flow collapsed to $12M in Q1 2026 from $103M in Q4 2025, suggesting seasonal weakness.

⚠ Company remains unprofitable with net losses in every quarter despite positive operating income throughout the period.

AI Insight: SGRY Ratio Trends

Operating margins remain volatile with 4.4pp swing from Q4 2025 to Q1 2026, while debt-to-equity ratio increased 38% since Q2 2024.

• Operating margin dropped from 12.4% in Q4 2025 to 8.1% in Q1 2026, continuing volatile quarterly performance.

• Debt-to-equity ratio climbed from 1.60 in Q2 2024 to 2.20 in Q1 2026, indicating rising leverage.

• ROIC improved from 4.7% in Q1 2025 to 4.9% in Q1 2026, though remains below mid-single digits.

⚠ Q1 seasonal weakness appears persistent with operating margins falling to ~8% in both Q1 2025 and Q1 2026.

⚠ Net profit margins remain consistently negative across all periods, with losses deepening in Q1 quarters.

Get alerted when SGRY's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Surgery Partners, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SGRY

BAIN CAPITAL INVESTORS LLC
$595.4M49,946,972 sh
JANUS HENDERSON GROUP PLC
$161.4M13,540,385 sh
Pentwater Capital Management LP
$150.8M12,655,000 sh
KING STREET CAPITAL MANAGEMENT, L.P.
$121.9M10,229,730 sh
UBS Group AG
$121.5M10,191,781 sh
BlackRock, Inc.
$67.5M5,660,788 sh
DIMENSIONAL FUND ADVISORS LP
$63.1M5,296,411 sh
Clearbridge Investments, LLC
$49.1M4,118,056 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$43.3M3,628,431 sh
VANGUARD CAPITAL MANAGEMENT LLC
$40.9M3,430,795 sh

Fund	Value	Shares
BAIN CAPITAL INVESTORS LLC	$595.4M	49,946,972
JANUS HENDERSON GROUP PLC	$161.4M	13,540,385
Pentwater Capital Management LP	$150.8M	12,655,000
KING STREET CAPITAL MANAGEMENT, L.P.	$121.9M	10,229,730
UBS Group AG	$121.5M	10,191,781
BlackRock, Inc.	$67.5M	5,660,788
DIMENSIONAL FUND ADVISORS LP	$63.1M	5,296,411
Clearbridge Investments, LLC	$49.1M	4,118,056
VANGUARD PORTFOLIO MANAGEMENT LLC	$43.3M	3,628,431
VANGUARD CAPITAL MANAGEMENT LLC	$40.9M	3,430,795

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SGRY on your watchlist

Track score changes the day Surgery Partners, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SGRY a good stock to buy?

13F Pro's AI-powered analysis of Surgery Partners, Inc. (SGRY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SGRY are available on the SGRY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SGRY?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SGRY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Surgery Partners, Inc.'s investment landscape.